Health Care & Life Sciences » Pharmaceuticals | Sinco Pharmaceuticals Holdings Ltd.

Sinco Pharmaceuticals Holdings Ltd. | Cash Flow

Fiscal year is January-December. All values HKD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
64,245.40
118,065.20
106,866.30
29,871.80
224,699.70
322,189.20
Depreciation, Depletion & Amortization
1,269.30
2,363.50
12,618.50
12,462.40
17,711.40
12,404.80
Other Funds
31,543.00
14,061.60
23,372.00
-
9,679.00
182,403.50
Funds from Operations
63,713.00
104,393.80
107,447.30
23,654.60
114,027.60
127,380.90
Changes in Working Capital
33,233.70
45,955.20
59,229.30
69,328.10
338,283.40
228,976.30
Net Operating Cash Flow
96,946.60
58,438.60
48,218.00
45,673.50
452,311.00
101,595.30
Capital Expenditures
113,328.80
52,439.10
39,056.90
49,984.90
34,364.30
Sale of Fixed Assets & Businesses
-
49.10
-
2,043.60
371.30
Purchase/Sale of Investments
-
-
-
123,253.00
124,626.80
Net Investing Cash Flow
113,328.80
52,390.10
66,193.50
240,934.90
83,005.00
Cash Dividends Paid - Total
-
6,292.60
-
5,430.80
-
Issuance/Reduction of Debt, Net
65,620.70
46,788.40
18,392.40
97,113.10
290,000.20
Net Financing Cash Flow
34,456.30
26,434.20
4,979.60
386,872.70
280,321.20
Net Change in Cash
18,151.10
32,421.00
12,347.10
109,683.00
90,434.30
Free Cash Flow
16,382.20
5,999.40
9,185.70
95,293.90
457,413.40
Net Assets from Acquisitions
-
-
27,136.60
69,740.60
7,628.80
Change in Capital Stock
378.50
-
-
295,190.40
-
Exchange Rate Effect
77.00
61.70
648.80
9,418.60
1,449.40

About Sinco Pharmaceuticals Holdings

View Profile
Address
E5-1805, Global Centre
Chengdu Sichuan 610041
China
Employees -
Website http://www.sinco-pharm.com
Updated 07/08/2019
Sinco Pharmaceuticals Holdings Ltd. engages in the marketing, promotion, and channel management services for pharmaceutical products and medical devices. It improves human plasma-based pharmaceutical, antibiotics, and other pharmaceuticals focused on therapeutic areas complementary to human plasma-based products. It offers human albumin solution, Axetine, Medocef, and Trifamox IBL.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.